Epitomics, Inc., an emerging biotechnology company, is dedicated to developing their breakthrough monoclonal antibody technology (RabMAb) for research, diagnostics and therapeutics. The Company has utilized a unique and proprietary RabMAb technology invented by scientists at Loyola University of Chicago and the University of California at San Francisco. This enabling platform produces high quality antibodies that have the potetial to be used in the broad areas of research, diagnostics and therapeutics.